HSBC Holdings
KYMR icon

HSBC Holdings’s Kymera Therapeutics KYMR Stock Holding History

HSBC Holdings’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,619
Closed -$597K – 3077
2025
Q4 		$597K Sell
7,619
-2,695
-26% -$182K ﹤0.01% 2222
2025
Q3 		$593K Buy
10,314
+3,120
+43% +$141K ﹤0.01% 2018
2025
Q2 		$318K Sell
7,194
-11,353
-61% -$391K ﹤0.01% 2403
2025
Q1 		$508K Buy
18,547
+1,064
+6% +$38.8K ﹤0.01% 2075
2024
Q4 		$702K Buy
17,483
+4,425
+34% +$200K ﹤0.01% 1981
2024
Q3 		$633K Sell
13,058
-5,124
-28% -$226K ﹤0.01% 1897
2024
Q2 		$546K Buy
18,182
+8,139
+81% +$282K ﹤0.01% 1932
2024
Q1 		$404K Sell
10,043
-142
-1% -$5.08K ﹤0.01% 2216
2023
Q4 		$260K Sell
10,185
-3,059
-23% -$54.7K ﹤0.01% 2352
2023
Q3 		$185K Buy
+13,244
New +$266K ﹤0.01% 2433
2022
Q4 		– Sell
-11,256
Closed -$253K – 3114
2022
Q3 		$253K Buy
+11,256
New +$297K ﹤0.01% 2505

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

HSBC Holdings's KYMR Position: Q1 2026 in Review

HSBC Holdings sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 7,619 shares — an estimated $597K sold.

HSBC Holdings first reported a position in KYMR in Q3 2022 and held it in 11 quarters. The position peaked at $702K in Q4 2024. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • HSBC Holdings reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HSBC Holdings sold 7,619 Kymera Therapeutics shares in Q1 2026, an estimated $597K.
  • HSBC Holdings first reported a position in Kymera Therapeutics in Q3 2022 and held it in 11 quarters.
  • HSBC Holdings's Kymera Therapeutics position peaked at $702K in Q4 2024.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.